Immunovia AB

Immunovia AB

Forskning inom bioteknik

Advancing early detection of pancreatic cancer

Om oss

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Bransch
Forskning inom bioteknik
Företagsstorlek
51–200 anställda
Huvudkontor
Lund
Typ
Publikt aktiebolag
Grundat
2007
Specialistområden
Pancreatic cancer, Early diagnosis of cancer, Cancer therapy monitoring, Patient classification, Blood-based tests, Antibody microarray technology, Serum biomarker signatures och Autoimmune diseases diagnosis, prognosis and therapy monitoring

Adresser

Anställda på Immunovia AB

Uppdateringar

Liknande sidor

Finansiering

Immunovia AB 5 rundor totalt

Senaste finansieringsrunda

Anslag

4 500 000,00 US$

Se mer info på crunchbase